Related Experiment Video

Updated: Jul 13, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.4K

Tumor microenvironment diversity and plasticity in cancer multidrug resistance

Zhi Li1, Peihao Yin2

  • 1Interventional Cancer Institute of Chinese Integrative Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China; Department of General surgery, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|October 13, 2023
PubMed

Insights

Multidrug resistance (MDR) in cancer is influenced by the tumor microenvironment (TME). Targeting TME elements offers a promising strategy to overcome MDR and improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer therapy.
  • The tumor microenvironment (TME) significantly impacts MDR development and reversal.

Purpose of the Study:

  • To review the dual role of the TME in promoting and reversing MDR in cancer.
  • To explore therapeutic strategies targeting the TME for overcoming MDR.

Main Methods:

  • Comprehensive literature review of research on TME and MDR.
  • Analysis of pathways through which TME influences MDR.
  • Evaluation of TME-targeted therapies.

Main Results:

  • The TME actively promotes MDR through various mechanisms.
  • Targeting specific TME components shows potential for MDR reversal.
  • The TME's adaptability can be exploited for therapeutic benefit.

Conclusions:

  • Understanding the TME's complex role is vital for effective cancer treatment.
  • Targeting TME factors, combination therapies, and innovative strategies can combat MDR.
  • Exploiting the TME may lead to personalized cancer treatment outcomes.
Keywords:
BufalinCancerHypoxia-inducible factorsMultidrug resistanceTumor microenvironment

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Heteromulticellular Stromal Cells in Scaffold-free 3D Cultures of Epithelial Cancer Cells to Drive Invasion09:18

Heteromulticellular Stromal Cells in Scaffold-free 3D Cultures of Epithelial Cancer Cells to Drive Invasion

Published on: April 4, 2025

601

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K